CD274 and adenocarcinoma: Doi et al. showed that pembrolizumab was active in pretreated esophageal cancer patients with PD-L1-expressing tumors (>1% PD-L1-positive tumor cells and/or tumor stroma), with a partial response (PR) rate of 30.4% (40.0% for adenocarcinoma, 29.4% for squamous cell); there were no complete responses (CR).